Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 3:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 507 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cell isolation Clear all

Conditions: Non-Hodgkin Lymphoma
Interventions: Carboplatin, Etoposide, Filgrastim, Ifosfamide, Leukapheresis, Plerixafor, Rituximab; Drug · Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Tumor, Solid
Interventions: agenT-797, Approved ICIs; Drug
Lead sponsor: MiNK Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 5 more

Conditions: Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Refractory, Primary Mediastinal Large B-Cell Lymphoma Recurrent, Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions: Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion, Leukapheresis; Drug · Procedure
Lead sponsor: Jennifer Crombie, MD; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Erectile Dysfunction
Interventions: Injection of adipose derived cells into penis; Device
Lead sponsor: Tissue Genesis; Industry
Eligibility: 21 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: San Diego, California • Washington D.C., District of Columbia • Gainesville, Florida + 2 more

Conditions: Diabetic Retinopathy
Interventions: blood draw; Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 98 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
Interventions: Busulfan, Cytarabine, Fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation; Drug · Procedure · Radiation
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: Up to 69 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: ADSCs administration; Biological
Lead sponsor: Arkansas Heart Hospital; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Little Rock, Arkansas

Conditions: COPD, Respiratory Insufficiency
Interventions: Lipoaspiration, AD-cSVF, Normal Saline IV; Procedure
Lead sponsor: Healeon Medical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Stevensville, Montana

Conditions: Liver Transplant
Interventions: arTreg, leukapheresis, cyclophosphamide, mesna, everolimus; Biological · Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lung Cancer, Metastatic Cancer
Interventions: isolated perfusion, paclitaxel, hyperthermia treatment; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Kidney Cancer
Interventions: dactinomycin, filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 0 Years to 15 Years
Enrollment: 3,031 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2003
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Healthy
Interventions: Leukapheresis; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Observational study no intervention; Other
Lead sponsor: University Hospital, Basel, Switzerland; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Miami, Florida + 11 more

Conditions: Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: methadone hydrochloride, morphine sulfate, oxycodone hydrochloride; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Spartanburg, South Carolina • Houston, Texas

Conditions: ESRD
Interventions: Immune Tolerance; Drug
Lead sponsor: Everett Meyer; Other
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 2
States / cities: Stanford, California • Madison, Wisconsin

Conditions: Recurrent Melanoma, Stage IV Melanoma
Interventions: temozolomide, flow cytometry, staining method, biopsy, laboratory biomarker analysis; Drug · Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chromosome Disorders
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1987 – 2003
U.S. locations: 5
States / cities: Chicago, Illinois • Boston, Massachusetts • Detroit, Michigan + 2 more

Conditions: Adenovirus Infection
Interventions: Adenovirus Specific T lymphocytes; Biological
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Up to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Acute Respiratory Distress Syndrome, Covid19
Interventions: T regulatory cells; Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetes
Interventions: Control, Pre-Isolation Infusion, Post-Isolation Infusion; Other · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Musculoskeletal Pain, Knee Osteoarthritis, Cartilage Injury, Cartilage Degeneration
Interventions: Autologous Mesenchymal Stem Cells; Biological
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
Interventions: pNGVL3-hICD vaccine, sargramostim, flow cytometry, immunologic technique, immunoenzyme technique, protein expression analysis, biopsy; Biological · Other · Genetic + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Alzheimer's Disease
Interventions: Liposuction under local anesthesia, Infusion of AD-SVF via IV and Intranasal; Procedure · Biological
Lead sponsor: Ageless Regenerative Institute; Industry
Eligibility: 55 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions: Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis, Nivolumab, Placebo Administration, Poly ICLC, Resection; Biological · Procedure · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 13 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

Evaluation of the Tissue Genesis Icellator Cell Isolation System to Treat Erectile Dysfunction

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD

Use of Autologous Stem/Stromal Cells In Chronic Lung Disorders: Obstructive (COPD) & Restrictive (RLD)

Liver Transplantation With Tregs at UCSF

Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors

Nodal Burden and Nodal Recurrence in Patients With Isolated Tumor Cells After Neoadjuvant Chemotherapy Treated With Axillary Dissection or Nodal Radiation: the OPBC-05/EUBREAST-14R/ICARO Study

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.

Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Noninvasive Prenatal Diagnosis: Using Fetal Cells From Maternal Blood

Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections

Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome

Nitrite Infusion in Islet Cell Transplantation

Impact of Mesenchymal Stem Cells in Knee Osteoarthritis

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant